Amgen, Mass General, Broad Institute Collaborate on New Drugs for IBD

By: Benzinga
Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ: AMGN ) announced today that they have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.